Atara Bio Announces Participation in Two Upcoming Immuno-Oncology Conferences

SOUTH SAN FRANCISCO, Calif., March 28, 2016 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced its participation in two upcoming immuno-oncology conferences:

• The 6th Annual William Blair and Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" Conference on Thursday, March 31, 2016 in New York, NY. 
  Dr. Chris Haqq, CMO of Atara Bio, will host a discussion entitled “The Power of Allogeneic T cell Banks Targeting Multiple Viral and Cancer Antigens” at 1:40 p.m. ET.

• Jefferies 2016 Immuno-Oncology Summit on Thursday, April 7, 2016 in Boston, MA. 
  Dr. Isaac Ciechanover, President and CEO of Atara Bio is scheduled to present at 7:30 a.m. ET, and will also host meetings with investors.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, with an initial focus on immunotherapy and oncology. Atara Bio's programs include T-cell product candidates and molecularly targeted product candidates. The T-cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.

INVESTOR & MEDIA CONTACT:

Investors: 	
Steve Klass		
212-213-0006 x331	
[email protected] 

Media:
Justin Jackson 
212-213-0006 x327
[email protected]